Vioxx Research Today is a free monthly online journal that collates and summarizes the latest research about Vioxx, including details on osteoarthritis, side-effects, trials, stroke, heart attack.

Volume 3 (2006), Issue 1 (January)

1. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
   Curr Med Res Opin, 22(1): 199-210. [Abstract] [Full-text]
2. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?
   Aliment Pharmacol Ther, 23(1): 27-33. [Abstract] [Full-text]
3. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
   Arthritis Rheum, 54(1): 282-91. [Abstract] [Full-text]
4. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
   Clin Cancer Res, 12(1): 214-22. [Abstract] [Full-text]
5. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
   Gastroenterology, 130(1): 55-64. [Abstract] [Full-text]
6. Synthesis of a NO-releasing prodrug of rofecoxib.
   J Org Chem, 71(2): 480-91. [Abstract] [Full-text]
7. Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.
   Chin J Dig Dis, 7(1): 1-6. [Abstract] [Full-text]
8. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.
   J Bone Miner Res, 21(2): 219-27. [Abstract] [Full-text]
9. Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach.
   J Pharmacol Exp Ther, 316(2): 547-55. [Abstract] [Full-text]
10. Does perioperative administration of rofecoxib improve analgesia after spine, breast and orthopaedic surgery?
    Eur J Anaesthesiol, 23(3): 219-26. [Abstract] [Full-text]
11. Acetaminophen for osteoarthritis.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
12. tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS).
    Mol Cell Biochem, 283(1): 159-67. [Abstract] [Full-text]

© 2004-2008 Vioxx Research Today. All Rights Reserved.